Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

QLS 31905

Next Previous
Drug Profile

QLS 31905

Alternative Names: anti-claudin 18.2/CD3 bispecific antibody; QLS-31905

Latest Information Update: 28 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Qilu Pharmaceutical
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Pancreatic cancer
  • Phase I/II Gastric cancer
  • No development reported Solid tumours

Most Recent Events

  • 28 Aug 2026 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease) in China (IV, Injection)
  • 21 Jul 2026 Qilu Pharmaceutical plans a phase III trial for Adenocarcinoma (First-line therapy, Combination therapy, Late-stage disease, Metastatic disease, Inoperable/Unresectable) in August 2026 (IV, Infusion) (NCT07716449)
  • 29 May 2026 Adverse events and efficacy data from a phase Ib/II trial in Pancreatic cancer and Gastric cancer presented at the 62nd Annual Meeting of the American Society of Clinical Oncology (AACR-2026)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top